Literature DB >> 35223873

Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder.

Pilar Carrillo1, Teresa Gorría2, Daniel Santana3, Maria Sepulveda3, Iban Aldecoa4,5,6, Blanca Gonzalez-Farré4,7, Esther Sanfeliu4,7, Eduard Mension1, Isaac Cebrecos1, Olga Martínez-Saez2, Imma Alonso1,8, Albert Saiz3,8.   

Abstract

INTRODUCTION: Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory central nervous system disorder that preferentially affects the optic nerve and the spinal cord. Although NMOSD is more commonly an idiopathic autoimmune condition associated with antibodies against aquaporin-4 (AQP4)-IgG, the disease may also occur as a paraneoplastic syndrome in rare instances. In these cases, the expression of AQP4 by the tumor is likely the trigger of the autoimmune response. CASE
PRESENTATION: We describe the case of a 32-year-old woman who presented with progressive tetraparesis, cranial involvement, respiratory failure, and spinal cord MRI compatible with longitudinally extensive transverse myelitis, few days after being diagnosed with a T3N1M0 triple-negative right breast cancer. Due to the history of concurrent breast cancer and after ruling out metastatic spinal cord involvement, the possibility of a paraneoplastic origin was raised. AQP4-IgG were found in the serum and CSF by cell-based assay, confirming the diagnosis of NMOSD. The patient was treated with corticosteroids, plasma exchange, and rituximab. Concomitantly, breast cancer therapy was started with an adapted neoadjuvant chemotherapy scheme based on carboplatin and paclitaxel. An initial slight improvement slowed down; so, a right mastectomy with lymphadenectomy was performed. Expression of AQP4 was demonstrated in the tumor. The patient presented a significant neurological improvement after combined treatment regaining muscular balance and strength in upper and lower extremities.
CONCLUSION: NMOSD may have a paraneoplastic origin associated with breast cancer and the importance of its early detection since the combination of tumoral and immunosuppressive therapy may improve the patient's prognosis.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Aquaporin-4; Breast cancer; Neuromyelitis optica; Paraneoplastic syndrome; Triple-negative breast cancer

Year:  2022        PMID: 35223873      PMCID: PMC8832250          DOI: 10.1159/000521578

Source DB:  PubMed          Journal:  Biomed Hub        ISSN: 2296-6870


  27 in total

1.  A case of paraneoplastic neuromyelitis optica associated with small cell lung carcinoma.

Authors:  Lisa M Deuel; Marjorie E Bunch
Journal:  J Neuroimmunol       Date:  2018-01-03       Impact factor: 3.478

2.  A possible paraneoplastic neuromyelitis optica associated with lung cancer.

Authors:  Giuseppe De Santis; Luisa Caniatti; Alessandro De Vito; Riccardo De Gennaro; Enrico Granieri; Maria Rosaria Tola
Journal:  Neurol Sci       Date:  2009-06-30       Impact factor: 3.307

3.  A paraneoplastic neuromyelitis optica spectrum disorder associated with a mature B-cell neoplasm.

Authors:  Shoko Nakayama-Ichiyama; Taiji Yokote; Nobuya Hiraoka; Kazuki Iwaki; Ayami Takayama; Kichinosuke Kobayashi; Toshikazu Akioka; Satoko Oka; Takuji Miyoshi; Takayuki Takubo; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Leuk Res       Date:  2011-03-11       Impact factor: 3.156

4.  Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation.

Authors:  Philippe Beauchemin; Raffaele Iorio; Anthony L Traboulsee; Thalia Field; Anna V Tinker; Robert L Carruthers
Journal:  Mult Scler Relat Disord       Date:  2017-12-23       Impact factor: 4.339

5.  Aquaporin-4 antibody positive short transverse myelitis associated with breast cancer.

Authors:  Weijing Liao; Cheng Li; Yulan Tang; Fan Huang; Huimin Kuang; Shuolin Liang; Yi Yang
Journal:  Mult Scler Relat Disord       Date:  2019-02-08       Impact factor: 4.339

Review 6.  New therapies for neuromyelitis optica spectrum disorder.

Authors:  Michael Levy; Kazuo Fujihara; Jacqueline Palace
Journal:  Lancet Neurol       Date:  2020-11-10       Impact factor: 44.182

7.  Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.

Authors:  Maria Sepúlveda; Nuria Sola-Valls; Domingo Escudero; Bojan Rojc; Manuel Barón; Luis Hernández-Echebarría; Begoña Gómez; Josep Dalmau; Albert Saiz; Francesc Graus
Journal:  Mult Scler       Date:  2017-09-18       Impact factor: 6.312

8.  Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer.

Authors:  Tomoya Kon; Tatsuya Ueno; Chieko Suzuki; Jinichi Nunomura; Shohei Igarashi; Tsugumi Sato; Masahiko Tomiyama
Journal:  J Neuroimmunol       Date:  2017-05-17       Impact factor: 3.478

9.  Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series.

Authors:  Raphaël Bernard-Valnet; Alvaro Cobo-Calvo; Aurore Siegfried; Raluca Marasescu; Mickael Bonnan; Guillaume Ballan; Emmanuel Ellie; Jan Bauer; Emmanuelle Uro-Coste; Romain Marignier; David Brassat
Journal:  Mult Scler Relat Disord       Date:  2019-04-01       Impact factor: 4.339

10.  Neuromyelitis optica spectrum disorder with lung adenocarcinoma and intraductal papillary mucinous neoplasm.

Authors:  Wei Fang; Yang Zheng; Meng-Ting Cai; Yin-Xi Zhang
Journal:  Mult Scler Relat Disord       Date:  2019-05-03       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.